Table 4.
Stage distribution according to diagnostic routes at each hospital, n (%)
|
Tumor stage
|
KU
|
|
|
WMC
|
|
|
|
Follow-up group (n = 271)
|
Symptomatic group (n = 480)
|
Cancer screening group (n = 128)
|
Follow-up group (n = 444)
|
Symptomatic group (n = 584)
|
Cancer screening group (n = 176)
|
|
| Stage 0 | 62 (22.9) | 22 (4.6) | 20 (15.6) | 154 (34.7) | 70 (12.0) | 61 (34.7) |
| Stage I | 89 (32.8) | 82 (17.1) | 50 (39.1) | 105 (23.7) | 80 (13.7) | 50 (28.4) |
| Stage II | 39 (14.4) | 113 (23.5) | 14 (10.9) | 67 (15.1) | 127 (21.8) | 25 (14.2) |
| Stage III | 43 (15.9) | 120 (25.0) | 23 (18.0) | 66 (14.9) | 177 (30.3) | 31 (17.6) |
| Stage IV | 38 (14.0) | 143 (29.8) | 21 (16.4) | 52 (11.7) | 130 (22.3) | 9 (5.1) |
| Early-stage | 151 (55.7) | 104 (21.7) | 70 (54.7) | 259 (58.3) | 150 (25.7) | 111 (63.1) |
KU: Kyoto University Hospital; WMC: Japanese Red Cross Wakayama Medical Center.